ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of ...

Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data “As the Company’s third-largest shareholder, we are deeply ...

Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes Acceleron Has Significant Momentum Given Recent Positive Data ...

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed ...

Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of ...

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies. Established in 2010 and headquartered in ...

Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 ...

Avoro Capital’s Behzad Aghazadeh is among the most prominent investors in biotech, delivering consistent returns at his $6 billion hedge fund. Speaking with STAT’s Adam Feuerstein late last year about ...

NEW YORK--(BUSINESS WIRE)--Avoro Ventures, a global venture capital firm investing in life sciences, announced the final close of its inaugural fund, Avoro Ventures Fund L.P. (“The Fund”), with $186 ...

Hedge funds specializing in life sciences and fledgling biopharma stocks posted varied results in March, when most stock indices fell sharply. Many funds made money, including one that surged by ...